CSIMarket Company Name, Ticker, Industry, else..


Revance Therapeutics Inc   (RVNC)
Other Ticker:  
 

Revance Therapeutics Inc

RVNC's Fundamental analysis



Looking into Revance Therapeutics Inc growth rates, revenue grew by 39.82 % in IV. Quarter 2023 from the same quarter a year ago. Ranking at No. 381

Major Pharmaceutical Preparations industry recorded deterioration of revenues by

Revance Therapeutics Inc 's net income grew by 1.06 % in IV. Quarter 2023 year on year, above company average,

• More on RVNC's Growth


Revance Therapeutics Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 10.84 in trailing twelve-month period.
Company
-
PE TTM   
Industry
341.95
PE TTM    
Company's Price to Sales ratio is at 1.38.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.37.


• More on RVNC's Valuation
 
 Total Debt (Millions $) 429
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 672,529
 Net Income/Employee (TTM) $ -862
 Receivable Turnover (TTM) 10.95
 Tangible Book Value (Per Share $) -1.91

Revance Therapeutics Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 10.84 in trailing twelve-month period.
Company
-
PE TTM   
Industry
341.95
PE TTM    
Company's Price to Sales ratio is at 1.38.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.37.


• More on RVNC's Valuation

•  Market Capitalization (Millions $) 322
•  Shares Outstanding (Millions) 85
•  Employees 348
•  Revenues (TTM) (Millions $) 234
•  Net Income (TTM) (Millions $) 0
•  Cash Flow (TTM) (Millions $) 30
•  Capital Exp. (TTM) (Millions $) -7
•  Total Debt (Millions $) 429
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 672,529
•  Net Income/Employee(TTM) $ -862
•  Receivable Turnover Ratio (TTM) 10.95
•  Tangible Book Value (Per Share $) -1.91

•  Market Capitalization (Millions $) 322
•  Shares Outstanding (Millions) 85
•  Employees 348
•  Revenues (TTM) (Millions $) 234
•  Net Income (TTM) (Millions $) 0
•  Cash Flow (TTM) (Millions $) 30
•  Capital Exp. (TTM) (Millions $) -7





  Ratio
•   Capital Ratio (MRQ) 3.8
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) -
•  Asset Turnover Ratio (TTM) 0.47
•  Inventory Turnover Ratio (TTM) 1.62





Revance Therapeutics Inc net profit margin of 182.11 % is currently ranking no. 8 in Major Pharmaceutical Preparations industry, ranking no. 14 in Healthcare sector and number 49 in S&P 500.

• More on RVNC's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com